No data to show
XKRX
302440
Market cap1.97bUSD
Apr 08, Last price
37,300.00KRW
1D
-0.93%
1Q
-28.13%
IPO
-77.60%
Name
SK Bioscience Co Ltd
Chart & Performance
P/E
130.94
P/S
7.91
EPS
284.86
Div Yield, %
—
Shrs. gr., 5y
107.44%
Rev. gr., 5y
33.19%
Revenues
369.51b
-19.10%
Net income
22.32b
-81.77%
CFO
29.35b
P
Earnings
May 12, 2025
Profile
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 369,505,556 -19.10% | 456,725,871 -50.84% | ||||
Cost of revenue | 338,772,125 | 302,391,700 | ||||
Unusual Expense (Income) | ||||||
NOPBT | 30,733,431 | 154,334,171 | ||||
NOPBT Margin | 8.32% | 33.79% | ||||
Operating Taxes | (14,990,492) | 19,281,233 | ||||
Tax Rate | 12.49% | |||||
NOPAT | 45,723,923 | 135,052,939 | ||||
Net income | 22,317,719 -81.77% | 122,451,950 -65.52% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 397,599 | 2,617,946 | ||||
BB yield | -0.01% | -0.05% | ||||
| Debt | ||||||
Debt current | 8,137,402 | 95,792,981 | ||||
Long-term debt | 33,009,655 | 47,320,949 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 527,842 | 2,648,749 | ||||
Net debt | (1,275,723,547) | (87,318,302) | ||||
| Cash flow | ||||||
Cash from operating activities | 29,346,361 | (124,958,284) | ||||
CAPEX | (50,295,489) | (76,489,443) | ||||
Cash from investing activities | (45,278,721) | 272,646,505 | ||||
Cash from financing activities | (89,582,616) | (19,867,162) | ||||
FCF | 41,501,495 | 44,335,516 | ||||
| Balance | ||||||
Cash | 1,274,141,241 | 1,480,805,573 | ||||
Long term investments | 42,729,362 | (1,250,373,341) | ||||
Excess cash | 1,298,395,326 | 207,595,939 | ||||
Stockholders' equity | 543,399,377 | 581,693,865 | ||||
Invested Capital | 1,181,557,309 | 1,629,875,111 | ||||
ROIC | 3.25% | 8.57% | ||||
ROCE | 1.78% | 8.40% | ||||
| EV | ||||||
Common stock shares outstanding | 77,014 | 77,021 | ||||
Price | 72,000.00 -2.04% | 73,500.00 -67.33% | ||||
Market cap | 5,544,987,408 -2.05% | 5,661,079,736 -67.11% | ||||
EV | 4,269,263,861 | 5,573,761,433 | ||||
EBITDA | 65,498,134 | 181,570,580 | ||||
EV/EBITDA | 65.18 | 30.70 | ||||
Interest | 1,398,139 | 2,460,940 | ||||
Interest/NOPBT | 4.55% | 1.59% | ||||